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OBJECTIVES: Through advances in molecular biology, new treatment options for
patients with metastatic renal cell carcinoma (RCC) have become available. Al-
though the efficacy of these new treatments has been demonstrated in large ran-
domised controlled trials, their effectiveness in daily practice is currently un-
known. The aim of this study was to evaluate the use of new treatment options for
patients with metastatic RCC in Dutch daily practice. METHODS: A population-
based registry has been created to collect data about patients diagnosed with met-
astatic RCC in 2008, 2009 and 2010. This registry contains data on patient and
tumour characteristics, treatment details (e.g., dosing) and response to treatment.
All patients living within the regions of four Dutch Cancer Registries are being
included in this study. Together these registries cover 55% of The Netherlands.
RESULTS: Forty-three patients, all diagnosed with metastatic RCC in 2008, are cur-
rently included in our registry. Of these, 47% received systemic therapy (mostly
sunitinib), while all others received surgery or palliative care. Patients treated with
sunitinib in Dutch daily practice were five years older and had a worse ECOG
performance status than patients treated with sunitinib in the pivotal phase 3 trial.
While the mean daily dose seen in Dutch daily practice in the first cycle was
comparable to the recommended dose (50 mg), the mean daily dose in the second
cycle was lower, i.e. 44 mg. CONCLUSIONS: The number of Dutch patients with
metastatic RCC treated with systemic therapy will increase because of new treat-
ments available since 2008. This study suggests that patients treated with systemic
therapy in daily practice have a different profile and receive different dose sched-
ules than patients treated in the pivotal trial. Consequently, the effectiveness of the
new treatment options in Dutch daily practice may also differ from what was seen
in the trial.
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TRENDS IN CHEMOTHERAPY AND BIOLOGIC TREATMENT OF US COLORECTAL
CANCER PATIENTS
Meyer N, Weldon D, Huse DM
Thomson Reuters, Cambridge, MA, USA
OBJECTIVES: To examine trends in chemotherapy and biologic regimens used in
1st, 2nd and 3rd line treatment of patients with colorectal cancer (CRC) in the US.
METHODS:Adult patients newly diagnosed with CRC from January 1, 2005- Decem-
ber 31, 2009 were selected from the Thomson Reuters MarketScan® Commercial
and Medicare Supplemental insurance claims databases. Patients were required to
have at least one cycle of chemotherapy and were followed from the administra-
tion of the first dose until the end of continuous insurance coverage or December
31, 2009, whichever came first. Evolution of first-, second-, and third-line treat-
ments from 2005 to 2009 is described. RESULTS: A total of 13,670 patients met the
study criteria. All had data on first-line treatment, 4,442 on second line, and 1,610
on third line. The most common first-line regimens were 5-fluorouracil (5-FU), 5-FU
and leucovorin (5-FU/LV), 5-FU/LV plus oxaliplatin (FOLFOX), and capecitabine.
Between 2005-2009, first-line use of FOLFOX increased from 25% to 35%, while use
of 5-FU/LV decreased from 18% to 7%. Second-line regimens were more diverse
with the most prevalent regimens being FOLFOX alone, FOLFOX plus bevacizumab,
5-FU/LV, and 5-FU/LV plus irinotecan (FOLFIRI) plus bevacizumab. Use of 5-FU/LV
as second-line treatment decreased from 12% in 2005 to 4% in 2009 as patients
received more diverse treatments. Between 2005-2009, third-line standard of care
moved toward biologic-containing regimens including FOLFIRI plus bevacizumab
and irinotecan plus cetuximab. Use of biologic regimens increased with each ther-
apy line and over time with 73% of third-line regimens in 2009 containing at least
one biologic compared with 57% in 2005. CONCLUSIONS:Over time the standard of
care chemotherapy for first-line CRC therapy has shifted away from 5-FU/LV to
FOLFOX, second line from 5FU/LV to more diverse treatments, and third line ther-
apy toward biologic containing regimens. Use of biologic regimens increased with
subsequent therapy line and over time.
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OBJECTIVES: To examine patient and disease characteristics and treatment pat-
terns among patients with chronic myeloid leukemia (CML) in multiple countries.
METHODS: Oncologists and hematologists in the United States (US), UK (UK), Ger-
many, and Japan abstracted medical charts of adult patients with CML between
January 1, 2005 and December 31, 2009. Patients were in chronic phase at diagnosis,
either Ph or BCR-ABL positive, had received first line treatment with imatinib, and
had not participated in a randomized clinical trial for CML. A subset of patients
received 2nd-line therapy with nilotinib or dasatinib. RESULTS: A total of 214 phy-
sicians provided data on 1,063 patients (range 220 – 300 per country). Patients were
55 years of age on average and 60% were male. Nearly 67% of patients did not have
any comorbidity, although when present, diabetes was most common in all coun-
tries (5% in Japan to 18% in Germany). Patients initiated imatinib within 3 months
after diagnosis, and received therapy for 22 months on average (19 months [US] to
25 months [Japan]), at a median daily dose of 400mg in all countries. Approximately
13% of patients (8% in Japan to 16% in UK) had a dose escalation to a median dose
of 800mg. 29% of patients discontinued imatinib, primarily due to resistance to
therapy or disease progression. 2nd-line treatment patterns were studied among
261 patients (148 dasatinib, 113 nilotinib). Patients in the US and Germany had
more nilotinib use (54%) while only 17% of UK patients used nilotinib. Patients
initiated 2nd-line therapy 25 months after initial diagnosis, and received treatment
for 11 months (dasatinib) or 7 months (nilotinib). More patients initiating dasatinib
had advanced disease (25% accelerated, 4% blast phase) compared to nilotinib (25%
accelerated, 1% blast phase). CONCLUSIONS: Patient characteristics and treat-
ment patterns in CML vary by country.
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AN EPIDEMIOLOGICAL EVALUATION OF CHEMOTHERAPY USED IN THE
TREATMENT OF METASTATIC PROSTATE CANCER
Chevalier P1, Moeremans K2
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OBJECTIVES: This retrospective study aimed at collecting real-life data regarding
chemotherapeutical treatments administered for metastatic prostate cancer in
Belgium. METHODS: From the Hospital Disease Database (year 2008), which in-
cludes data on full hospitalizations and day clinic for 34.3% of Belgian hospital
beds, stays of patients with metastatic prostate cancer were selected based on the
combination of ICD-9-CM codes for prostate cancer (185) and metastasis (196-197-
198-199). Chemotherapy sessions were identified using the ICD-9-CM code V58.1.
Identification of chemotherapeutical regimens was based on drug names. In addi-
tion, grade III/IV haematologic toxicities were identified using ICD-9-CM codes.
RESULTS: Among the 1171 patients identified with metastatic prostate cancer in
2008, 387 ( 33%) were administered chemotherapy. The total number of chemo-
therapies administered was 521; 272 patients (70.3%) received only one regimen, 97
(25.1%) received two different regimens, 17 (4.4%) and 1 (0.3%) patient received
respectively three and 4 regimens during the year. For 38.7% of chemotherapies,
the regimen could not be identified. These may represent chemotherapies admin-
istered in clinical trial or compassionate use setting. 201 (51.9%) of chemotherapy
patients received at least one docetaxel-containing regimen. 194 (50.1%) received
docetaxel monotherapy and 10 (2.6%) received docetaxel in combination with an-
other chemotherapeutical agent. The second most commonly identified regimen
was mitoxantrone monotherapy, administered to 39 patients (10.1%): 22 of them
had received prior docetaxel within the same calendar year. The average number of
cycles was 5.83 for docetaxel and 3.27 for mitoxantrone. Other chemotherapy reg-
imens included carboplatin-, fluorouracil- and cisplatin-containing regimens (re-
spectively 4.9%, 3.9% and 2.6% of patients). Among the patients treated with che-
motherapy, 21 (5.4%) developed (febrile) neutropenia, 90 (23.3%) had anemia and 37
(9.6%) had thrombocytopenia.CONCLUSIONS:This study shows that real-life prac-
tice is in line with the European guidelines, recommending docetaxel as first option
for chemotherapy in metastatic prostate cancer.
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TREATMENT PATTERNS IN PATIENTS WITH METASTATIC MELANOMA
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OBJECTIVES: To describe treatment patterns in patients with metastatic mela-
noma (MM) in the US. METHODS: Using a large US medical claims database, pa-
tients were identified between 2005 and 2010 using 2melanoma diagnoses (ICD-
9-CM: 172.xx, V10.82) and 2 diagnoses for metastasis (ICD-9-CM: 197.xx, 198.xx).
The index date was the first date of metastasis diagnosis. Patients who had other
primary malignant tumors prior to the melanoma diagnosis, were younger than 18
years old at the index, or had a pre-index period of less than 6 months, were
excluded from the analysis. Patients were followed from the index date to death,
disenrollment, or end of the study period (June 30, 2010), whichever occurred first.
Drug, surgery, and radiation therapy were examined descriptively. The trend of
treatment patterns over the years was also examined. RESULTS:A total of 2546 MM
patients who met the study inclusion and exclusion criteria were included in the
analyses. Mean ( standard deviation) age was 60.6 ( 14.0) years old and 36.5%
were female. Mean length of follow-up observation period was 322 days. The most
common site of metastasis at the index date was lung (21.2%), brain and spinal cord
(18.7%), distant area of the skin (11.4%), bone (11.2%), and liver (10.0%). Overall,
56.8% of patients received cancer-related surgery, 38.7% received drug treatment,
and 44.7% received radiation therapy after MM diagnosis. Among patients who
received drug treatment, 48.7% received temozolomide, 22.3% paclitaxel, 19.4%
carboplatin, 17.6% interleukin-2 (IL-2), 17.2% dacarbazine (DTIC), 14.4% interferon
alfa-2b (IFN), 9.9% cisplatin, 6.3% vinblastine, 4.7% granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF), 4.5% docetaxel, 2.0% carmustine, and 0.2% bacillus
calmette-guerin (BCG). CONCLUSIONS: Approximately 39% of MM patients were
treated with chemotherapy or immunotherapy and this pattern remained similar
during the last decade, which suggests an unmet need for patients with advanced
melanoma.
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CANCER (MCRC)? THE RESULTS OF LARGE POPULATION BASED SURVEY IN
GERMANY 2009
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OBJECTIVES: The survey was initiated to gain insights into the implementation of
decision-making tools in national guidelines in treatment patterns of mCRC in
daily practice. The tools define treatment intensity for subgroups of patients by
clinical characteristics and anticipated treatment aims. METHODS: Physicians in
representative sample of centres (69) reported all pts. with treatment decision in
October-December 2009. The database contains 1019 pts. with retrospective record
of treatment history. Treatment decisions were analysed in 3 predefined subgroups
according to a model based on the German guidelines. Statistics were performed in
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SPSS by bivariate analyses with two-sided Chi-square test. In the next step the
subgroups of patients with comparable treatment in clinical practice were defined
and analysed in a multivariate analysis. RESULTS: By contrast to the recommen-
dation of national guidelines, intensified therapy was administered less frequently
in patients with the aim of “resection of metastases” (43%), whereas the highest use
(64%) was reported in “patients with tumor related symptoms or at risk for rapid
progression or deterioration”. This group represents only 12% of the 1st line. Fac-
tors with an influence on the use of intensified therapy in daily practice were
analyzed in a multivariate analysis. Three treatment clusters (comprising 89% of
patient sample) were determined. (all p0,05) The cluster with significantly higher
use of intensified therapy (18% above mean value of 54%) is distinguished by: Age
70 y., better PS (80% KI), no symptoms and/or without concomitant diseases,
treatment in office based setting. Patients in this cluster show less tumor
dynamics. CONCLUSIONS: In daily practice, the application of the decision model
based on treatment aims for clinical subgroups is not generally used. Intensified
treatment is more likely associated with individual patient characteristics and
institutional framework. This, however, underlines the need for a critical discus-
sion of the currently suggested decision-making models.
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OBJECTIVES: Reimbursement agencies require estimates of the long-term (i.e. life-
time) costs and benefits associated with each treatment option as part of the deci-
sion making process. As such, extrapolation of reported survival estimates is inev-
itable. Conventionally, information on all-cause mortality or disease progression is
used. However, data for newly diagnosed CML may not be suited to such an extrap-
olation due to the paucity of observed events. One of solutions is to use a ‘surrogate
approach’.METHODS: A 40 year Excel® based model was created to estimate over-
all (OS) and progression-free (PFS) survival in newly diagnosed CML patients re-
ceiving 1st or 2nd generation tyrosine kinease inhibitor (TKI) therapy through the
use of a surrogate clinical endpoint (cytogenic response - CyR). Three response
categories (complete, partial or no CyR at one year) were used. Long term response
category specific OS and PFS data from IRIS clinical trial was used to inform the
fitting of Weibull functions with goodness of fit assessed via the R2 statistic. CyR
response rates were taken from a recently published network meta-analysis of
first-line interventions. RESULTS: Using the conventional approach, CML patients
were predicted to have an equivalent survival profile to the non-CML general pop-
ulation (31.6 versus 32.6 years), and the survival difference between 1st and 2nd
generation drugs are 9 years (31.6 versus 22.8 years) (Botteman et al 2010). However,
predicted OS estimates for 1st and 2nd generation TKI’s using the surrogate ap-
proach are 18.6 and 20.1 years respectively (R2 values 0.97, 0.94). Compared to 1st
generation drugs the use of 2nd generation TKI’s results in approximately 1.5 ad-
ditional years of survival. CONCLUSIONS: Extrapolating short term overall OS data
in newly diagnosed CML results in inflated survival estimates. When a valid clinical
surrogate is used there is a much smaller, and believable, difference in the pre-
dicted survival values.
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OBJECTIVES: Progression-free survival (PFS) is frequently used to establish the
clinical efficacy of anti-cancer drugs. However, this surrogate measure of survival
is of limited interest for the economic evaluation of these treatments. Therefore,
the aim of this study is to develop a predictive model for OS based on PFS data in the
context of metastatic breast cancer (mBC), which would be suitable for cost-effec-
tiveness (cost per life-year saved) and cost-utility analyses. METHODS: A system-
atic review of the literature was conducted according to the PICO method: Popula-
tion consisted of women with mBC; Interventions and Comparators were standard
treatments for mBC or best supportive care; Outcomes of interest were median PFS
and median OS. All selected studies were randomized trials published from 1990 to
2010. Two independent reviewers screened titles, abstracts, and full papers for
eligibility. Then, reviewers independently extracted data from selected studies
(median PFS, median OS, and potentially predictive covariates). The relationship
between PFS and OS was assessed by calculating Pearson’s correlation coefficient.
Finally, statistical analyses (ANOVA and Pearson’s correlation) were performed to
identify covariates having a significant impact on OS. RESULTS: A total of 5041
studies were identified and 151 fulfilled the eligibility criteria. According to the data
extracted from selected studies, there is a significant relationship between median
PFS and median OS (r0.373;p0.01). Moreover, many covariates have a statisti-
cally significant impact on OS including age (p0.01), type of treatment (p0.01),
line of treatment (p0.01), ECOG status (p0.01), and number and sites of metas-
tasis (p0.01). CONCLUSIONS: Results of this systematic review point toward a
significant relationship between PFS and OS in the context of mBC. These findings
will enable the development of a predictive model for OS based on PFS and signif-
icant covariates, which will eventually bring answers to an important challenge in
the economic evaluation of anti-cancer drugs.
PCN191
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OBJECTIVES: To compare the costs of XELOX (Xeloda  Oxaliplatin) and FOLFOX4
(5-FU  Oxaliplatin  Leucovorin) for adjuvant treatment of stage III colon cancer
in a South Korean setting. METHODS: Based on the equivalence in efficacy of
XELOX from NO16968 trial and FOLFOX4 from MOSAIC trial (the 5 yrs disease free
survival rates were very similar 66.1% for XELOX and 66.4% for FOLFOX4), a cost-
minimization approach was chosen. The model adopts a payers perspective. Effi-
cacy/Safety data and protocol information were acquired from NO16968 for XELOX,
and from the MOSAIC trial for FOLFOX4. As no direct comparison of XELOX and
FOLFOX4 for this indication is available, we collected several medical resource use
data for these two regimens, which were chemotherapy drug doses, adverse
events, hospitalization-ambulatory visits, and drug administration methods. The
medical costs for FOLFOX4 were acquired from real world claims data (electronic
data interchange, EDI); Catholic medical center in Korea. The direct medical costs
for XELOX were also estimated by EDI from Catholic medical center with NO16968
trial. Also, health care utilizations were measured. All data analyses were per-
formed using STATA software. RESULTS: The total direct medical costs for XELOX
were estimated to be 13,884,894 KRW and for FOLFOX4 14,509,341 KRW per patient
for 24weeks of chemotherapy treatment at same body surface area. The drug costs
of XELOX were 12,468,748 KRW and of FOLFOX4 10,831,699 KRW. The line costs and
drug administration costs were 82,960 KRW for XELOX and, 943,176 KRW for FOL-
FOX4, respectively. XELOX is more expensive in terms of drug acquisition costs.
However, this is more than compensated by cost savings for drug administration,
ambulatory encounters, AE medications, costs for central venous lines, and hospi-
talization. Additional incidence of hospitalization for FOLFOX4 was 2.3 times
greater than for XELOX related hospitalization. CONCLUSIONS: XELOX offers cost
savings of 644,447 KRW (about 585 US $) per patient compared to FOLFOX4 from the
payers perspective in South Korean Universal Health Insurance System.
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INTO STANDARD TREATMENT : EXAMPLE FROM CROATIA
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OBJECTIVES: In order for a new therapy to be included and reimbursed on the basic
list of treatments covered by Croatian Institute for Health Insurance (HZZO), it
must prove to have a positive effect on the budget impact analysis (BIA). The
standard therapy for patients suffering from advanced head and neck cancer is
chemoradiotherapy (mainly platinum and radiotherapy). However, if chemother-
apy proves to be contraindicative, only radiotherapy is applied. Cetuximab inhibits
EGFR, which induces the apoptosis of cancer cells. It has been proven that the
implementation of immunoradiotherapy contributes to the overall survival of
patients. METHODS: Known costs of the standard therapy for advanced head and
neck cancer were compared with the costs of the proposed new therapy (cetux-
imab radiotherapy). The costs are shown in the croatian currency (HRK) (1 Euro
7,4 HRK). The increased costs of immunotherapy are compared to the data on
efficiency from published literature. RESULTS: Approximately 212 patients with
advanced head and neck cancer receive treatment in Croatia every year. If chemo-
therapy is contraindicative, a standard radiotherapy is applied (42 patients). The
HZZO spends yearly 840.000,00 HRK on the treatment of those patients. The inclu-
sion of cetuximab into the standard therapy would increase the total yearly costs
by 3,082.650,90 HRK. When compared to radiatiotherapy, immunoradiotherapy
prolongs the control of the illness (14,9 vs. 24,4 months), and the overall survival of
patients (29,3 vs. 49,0 months). The cost for one added life-year per patient, would
be approximately 89.738,00 HRK. CONCLUSIONS: The inclusion of immunotherapy
into the standard treatment of patients with advanced head and neck cancer would
have a negative impact on the budget of the HZZO. The average costs for one added
life-year are lower than the average costs of chronic kidney insufficiency patients.
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USING WHOLE DISEASE MODELLING TO INFORM ECONOMIC
RECOMMENDATIONS FOR THE DETECTION, DIAGNOSIS, TREATMENT AND
FOLLOW-UP OF COLORECTAL CANCER
Tappenden P, Brennan A, Chilcott J, Squires H
University of Sheffield, Sheffield, South Yorkshire, UK
OBJECTIVES: Conventional economic evaluation typically involves piecewise com-
parisons of competing technologies at a single isolated point in a broader care
pathway. This study assesses the value of simulating whole disease and treatment
pathways to provide a common economic basis for informing resource allocation
decisions across an entire disease service. This Whole Disease Modelling ap-
proach was applied to the evaluation of technologies for the detection, diagnosis,
treatment and follow-up of colorectal cancer. METHODS: A patient-level simula-
tion model was developed with the intention of informing NICE’s colorectal cancer
clinical guideline. The model simulates disease and treatment pathways from pre-
clinical disease through to detection, diagnosis, adjuvant treatment, follow-up,
treatments for metastases and supportive care. The model was populated using
randomised trials, observational studies, health utility studies, costing sources and
expert opinion. Unobservable natural history parameters were calibrated against
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